Suppr超能文献

他汀类药物的药理学特性。

Pharmacologic characteristics of statins.

作者信息

McKenney James M

机构信息

National Clinical Research, Inc., and School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, USA.

出版信息

Clin Cardiol. 2003 Apr;26(4 Suppl 3):III32-8. doi: 10.1002/clc.4960261507.

Abstract

Considerable effort has been devoted to improving the pharmacologic characteristics and clinical effects of statins. Desirable pharmacologic properties include potent inhibition of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase, selectivity of uptake in hepatocytes, low systemic bioavailability to reduce systemic adverse effects, prolonged elimination half-life, and no or minimal hepatic metabolism to avoid drug-drug interactions. The desirable effects on lipid variables would include increased effectiveness in reducing levels of low-density lipoprotein cholesterol and other atherogenic lipoproteins and measurable beneficial effects on high-density lipoprotein cholesterol levels. As a product of the ongoing efforts regarding statin pharmacology, the new statin rosuvastatin exhibits significant improvements in several of these characteristics.

摘要

人们已付出相当大的努力来改善他汀类药物的药理学特性和临床效果。理想的药理学特性包括对羟甲基戊二酰辅酶A(HMG-CoA)还原酶的强效抑制、在肝细胞中的摄取选择性、降低全身不良反应的低全身生物利用度、延长消除半衰期以及无或极少的肝脏代谢以避免药物相互作用。对脂质变量的理想作用包括在降低低密度脂蛋白胆固醇和其他致动脉粥样硬化脂蛋白水平方面提高有效性,以及对高密度脂蛋白胆固醇水平产生可测量的有益作用。作为他汀类药物药理学持续研究的成果,新型他汀类药物瑞舒伐他汀在其中几个特性方面有显著改善。

相似文献

1
Pharmacologic characteristics of statins.
Clin Cardiol. 2003 Apr;26(4 Suppl 3):III32-8. doi: 10.1002/clc.4960261507.
2
Optimizing the pharmacology of statins: characteristics of rosuvastatin.
Atheroscler Suppl. 2002 Apr;2(4):33-6; discussion 36-7. doi: 10.1016/s1567-5688(01)00016-2.
3
Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia.
Heart Dis. 2003 Jan-Feb;5(1):72-8. doi: 10.1097/01.HDX.0000050417.89309.F8.
4
Rosuvastatin: a high-potency HMG-CoA reductase inhibitor.
J Am Pharm Assoc (2003). 2005 Jul-Aug;45(4):503-13. doi: 10.1331/1544345054475522.
5
Efficacy and safety of rosuvastatin in treatment of dyslipidemia.
Am J Health Syst Pharm. 2005 May 15;62(10):1033-47. doi: 10.1093/ajhp/62.10.1033.
6
New dimension of statin action on ApoB atherogenicity.
Clin Cardiol. 2003 Jan;26(1 Suppl 1):I7-10. doi: 10.1002/clc.4960261304.
7
Comparative pharmacology of rosuvastatin.
Atheroscler Suppl. 2003 Mar;4(1):9-14. doi: 10.1016/s1567-5688(03)00004-7.
9
[Pharmacologic characteristics of rosuvastatin, a new HMG-CoA reductase inhibitor].
Therapie. 2003 Mar-Apr;58(2):113-21. doi: 10.2515/therapie:2003016.

引用本文的文献

1
Embryotoxicity of statins and other prescribed drugs with reported off-target effects on cholesterol biosynthesis.
Reprod Toxicol. 2025 Mar;132:108820. doi: 10.1016/j.reprotox.2024.108820. Epub 2024 Dec 10.
2
Statins-Their Role in Bone Tissue Metabolism and Local Applications with Different Carriers.
Int J Mol Sci. 2024 Feb 17;25(4):2378. doi: 10.3390/ijms25042378.
3
Statins-From Fungi to Pharmacy.
Int J Mol Sci. 2023 Dec 29;25(1):466. doi: 10.3390/ijms25010466.
4
Correlation between Statin Solubility and Mortality in Patients on Chronic Hemodialysis.
Diagnostics (Basel). 2023 Oct 23;13(20):3290. doi: 10.3390/diagnostics13203290.
6
Effects of Statin Combinations on Zika Virus Infection in Vero Cells.
Pharmaceutics. 2022 Dec 23;15(1):50. doi: 10.3390/pharmaceutics15010050.
9
Detection of statin-induced rhabdomyolysis and muscular related adverse events through data mining technique.
BMC Med Inform Decis Mak. 2022 Sep 5;22(1):233. doi: 10.1186/s12911-022-01978-4.

本文引用的文献

3
Optimizing the pharmacology of statins: characteristics of rosuvastatin.
Atheroscler Suppl. 2002 Apr;2(4):33-6; discussion 36-7. doi: 10.1016/s1567-5688(01)00016-2.
7
Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia.
Am J Cardiol. 2001 Aug 1;88(3):270-4. doi: 10.1016/s0002-9149(01)01639-3.
9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验